INTRODUCTION
T HE 14-3-3 PROTEINS ARE THE PROTOTYPE for a novel class of protein modules that can recognize phosphoserine/threonine (pS/T)-containing motifs used by a variety of signal transduction pathways. [1] [2] [3] [4] [5] [6] [7] To date, 14-3-3 proteins have been reported to bind more than 200 client proteins. [8] [9] [10] Through these interactions, 14-3-3 proteins play important roles in a wide range of vital regulatory processes, such as Bad-induced apoptosis, Raf-1-mediated cell proliferation, and Cdc25-regulated cell cycle progression. In addition to their participation in diverse physiological processes, 14-3-3 proteins have been implicated in a number of clinically important pathological conditions, such as neurodegenerative disorders and cancers. [11] [12] [13] Thus, such studies on the 14-3-3/client-protein interactions may provide tremendous opportunities for therapeutic interventions. However, no chemical tools are available that allow pharmacological probing of 14-3-3 function under in vivo conditions. As a 1st step to target 14-3-3, short peptide inhibitors of 14-3-3 were developed based on screening of phage display libraries. 14 A high-affinity peptide, termed R18, has been identified and well studied. The specificity of R18 for 14-3-3 has been confirmed by an affinity pull-down assay, mutational analysis, and cocrystallization analysis. [14] [15] [16] Functionally, R18 and its derivative difopein can specifically disrupt the interaction of 14-3-3 with a broad range of cellular proteins, such as Raf-1. 14, 15 R18 and difopein have been widely used to probe the function of 14-3-3/clientprotein interactions in various biological systems and in proteomics studies. 8-10 14-3-3 has a role in promoting cell survival and resistance of cells to cytotoxic agents, as shown by the ability of R18 to enhance cell death induced by anticancer drugs such as cisplatin. 15 Other examples of peptide 14-3-3 antagonists include those derived from natural 14-3-3 binding proteins. One such antagonist is the penetratin-linked AARAApSAPA peptide (AP-pSAPA). 17 AP-pSAPA, when transduced into cells, blocked the IGF-1-induced binding of 6-phosphofructo-2-kinase to 14-3-3. However, delivery of a peptide inhibitor into cells or animals and the instability of these peptides in vivo pose significant obstacles for mechanistic and therapeutic exploration.
Nonpeptide small-molecule 14-3-3 inhibitors would greatly facilitate such work. Although protein-protein interactions are generally difficult to disrupt, recent studies have yielded some successes, such as small-molecule inhibitors for the MDM2/p53 interaction and the Smac/XIAP association. [18] [19] [20] In support of the strategy to target 14-3-3 proteins with a small molecule, a single charge-reversal mutation, K49 to E, in the amphipathic groove of 14-3-3 is sufficient to disrupt the 14-3-3/client-protein interaction. 21 These results demonstrate, in principle, the feasibility to disrupt the 14-3-3/client-protein interaction with a small molecule.
Here we report the design and development of a simple, homogeneous fluorescence polarization (FP) assay for monitoring 14-3-3 protein interactions. The FP method measures increased polarization of emitted light in response to decreased rotation of the labeled molecule, for example, through protein complex formation (see references 22-28 and references therein). By using the interaction of 14-3-3 with a rhodamine-labeled peptide derived from a well-studied 14-3-3 binding protein, Raf-1, we have designed and optimized a highly sensitive FP assay and achieved a simple 1-step "mix-and-measure" method for 14-3-3 proteins. This is a versatile method that can be used to monitor the binding of 14-3-3 with a variety of client proteins. Because of its simplicity, it is particularly suited for high-throughput screening (HTS) to isolate smallmolecule 14-3-3 inhibitors or stabilizers. Indeed, our FP assay has achieved a robust performance for HTS in a 384-well format with a demonstrated signal-to-noise ratio greater than 10 and a Z′ factor greater than 0.7. Such a validated assay can be readily used for screening large chemical compound libraries in an HTS format to identify small molecules that disrupt the interaction of 14-3-3 with its protein partners.
MATERIALS AND METHODS
All of the reagents were of highest purity and were obtained from Sigma Chemical Co. (St. Louis, MO), unless otherwise as stated.
Fluorescent peptide probe and peptide antagonists
The peptide sequence containing phosphorylated S259 of Raf-1 was synthesized and labeled with 5/6 carboxytetramethylrhodamine (TMR; Anaspec, San Jose, CA). The TMR-pS259-Raf contains 15 residues: 5/6-TMR-LSQRQRST[pS]TPNVHM, which was dissolved in the HEPES reaction buffer (pH 7.4; see below). The following peptides were synthesized and purified at the Emory Microchemistry and Proteomics Facility: Biotin-pS259-Raf, pS967-ASK1 (GSNEYLKSI[pS]LPVP 2 9 ), R18 (PHCVPKNLSWLNLEAN MCLP 14 ) , and the mutated R18, R18Lys, where D12 and E14 were changed to K. 15
Expression and purification of recombinant 14-3-3 proteins
The recombinant GST-14-3-3γ protein was expressed in Escherichia coli strain BL21 (DE3) as a GST-tagged product as described. 30 E. coli BL21 (DE3) strains were grown in LB medium with ampicillin (100 µg/mL) for protein auto-induction. After overnight at 37°C, the cells were harvested and the pellet was resuspended in ice-cold phosphate-buffered saline (PBS) buffer composed of phenylmethylsulfonyl fluoride (PMSF, 1.0 mM), leupetin (1 µg/mL), and aprotinin (1 µg/mL). The GST-14-3-3γ protein was then purified by using Glutathione-Sepharose beads (GE Healthcare, Piscaraway, NJ), and the bound protein was eluted in a PBS buffer (pH 9) containing reduced glutathione (20 mM), PMSF (0.25 mM), dithiothreitol (DTT; 5 mM), and Triton X100 (0.1%). Salts were removed from the pooled elution fractions containing GST-14-3-3γ protein fusion using a PD-10 gel filtration column (GE Healthcare) equilibrated in HEPES buffer (pH 7.4). The protein concentration was measured using the Bradford method (BioRad), and GST-14-3-3γ was stored at -20°C before use. The recombinant hexaHis-tagged 14-3-3 isoforms were expressed and purified essentially as previously described. 31
Fluorescence polarization measurements
The reaction buffer used in the FP assay throughout this study contains HEPES (10 mM, pH 7.4), NaCl (150 mM), Tween-20 (0.05%), and DTT (0.5 mM). FP measurements were performed using black 384-well microplates (Corning Costar, Cambridge, MA) on an Analyst HT plate reader (Molecular Devices, Sunnyvale, CA). An integration time of 100 ms was used, and Z height was set at 2.15 mm (middle). The excitation polarization was set at "static," and emission polarization was set at "dynamic." For TMR-labeled probe, an excitation filter at 545 nm and an emission filter at 610 to 675 nm were used with a dichroic mirror of 565 nm. All fluorescence polarization values were expressed as the millipolarization (mP) units. 28 The assay window is calculated as the difference between the FP value recorded for the bound peptide and the FP value recorded for the free peptide probe.
Assay development and optimization
The 14-3-3 FP assay was carried out in black 384-well microplates in a total volume of 50 µL in each well or as specified. For each assay, 2 basic solutions were prepared. Solution A contained TMR-pS259-Raf peptide in the reaction buffer (2× solution with 2 nM of the peptide probe or as specified). Solution B contained 14-3-3 proteins in the reaction buffer (2× solution with 1 µM of 14-3-3 or serial dilutions of a specified concentration, as described in the legends to the figures, or without 14-3-3 proteins as control samples). For basic assays, an equal volume (25 µL) of solution A and solution B was mixed and incubated for 60 min at room temperature (RT) or a defined period of time. The polarization value in mP was measured at RT with an Analyst HT reader.
For assay performance, the signal-to-noise ratio (S:N) and the Z′ factor were calculated based on the following equations 32 
where SD b and SD f are the standard deviations for bound ( b ) and free ( f ) peptides without 14-3-3, whereas µ b -µ f is the difference in mean signals for bound and free peptides, and Z′ factor = 1 -(3 SD b + 3 SD f )/(µ b -µ f ), where the Z′ factor reflects the quality of the assay itself without intervention of test compounds. All experimental data were analyzed using Microsoft Excel (Microsoft Corporation, Redmond, WA) and Prism 4.0 (Graphpad Software, San Diego, CA).
Competitive FP assay
For the peptide competition studies, FP assays were performed in a 384-well format with TMR-pS259-Raf (1 nM), GST-14-3-3γ (0.5 µM, or as specified), and serial dilutions of competitive peptides dissolved in reaction buffer in a final volume of 50 µL. TMR-pS259-Raf peptide only (free peptide) and TMR-pS259-Raf peptide with GST-14-3-3γ (bound peptide) were included as controls in each plate. The polarization values were measured after 60 min of incubation at RT. The competitive effect was expressed as the percentage of control. IC 50 values were determined from the model with nonlinear regression analysis.
HTS format
To evaluate the quality or suitability of the FP assay for HTS, the assay windows, the Z′ factors, and the S:N ratios were determined from assays carried out in 40 microplates (384-well format). Two different volumes were employed, 50 µL or 20 µL. Each 384-well plate contained 8 wells of free TMR-pS259-Raf peptide control and 8 wells of bound TMR-pS259-Raf peptide control (with GST-14-3-3γ, 0.5 µM). The mP value for each well was obtained and analyzed, and means of both free and bound peptide controls from each assay plate were obtained and analyzed by scatter plot. The Z′ factor and the S:N ratios were calculated as described.
RESULTS AND DISCUSSION

Development of 14-3-3 protein fluorescence polarization assay
FP is a very powerful and sensitive nonradioactive technique for the study of molecular interactions in solution. [22] [23] [24] [25] [26] [27] [28] This method can be used to measure binding and dissociation between 2 molecules if 1 of the binding molecules is relatively small and fluorescent. When fluorescent small molecules (such as a small peptide) in solution are bound to bigger molecules (such as a protein), the movement of the complex becomes slower. When such a complex is irradiated with polarized light, much of the emitted light is also polarized because the complex moves slowly relative to the time it takes the excited fluorophore to emit a photon. Thus, the binding of a fluorescently labeled peptide to a protein can be monitored by the change in polarization. We reasoned that this assay format might be particularly suited to the study of 14-3-3 proteins because the interaction of 14-3-3 proteins with their associated proteins is generally mediated by well-defined short peptide motifs in the client proteins. 6,7 Such 14-3-3 recognition motifs can be synthesized and labeled for FP assay development.
Initially, we used an FP assay based on the interaction of 14-3-3 with a fluorescently labeled R18 to dissect the role of the 14-3-3 Cterminal sequence in ligand binding (see supplementary materials in Truong et al. 33 ). However, this assay gave a relatively high background signal. To develop a robust FP assay with reduced background polarization using a natural client protein, we used the well-studied interaction of 14-3-3 with Raf-1. [1] [2] [3] [4] The TMR-pS259-Raf peptide (2 nM in a 2× solution) was mixed in a 1:1 ratio with various concentrations of GST-14-3-3γ solution (2×), and FP was measured. The initial concentration of the TMR-pS259-Raf was chosen based on the observation that 1 nM of the TMR-labeled peptide exhibited about 10 times more fluorescence intensity in the parallel channel than the "buffer-only" control samples. Interaction of 14-3-3 with TMR-pS259-Raf gave rise to a significant FP signal with a minimal background polarization with the peptide probe alone (Fig. 1) . As shown in Figure 1A , with increasing amounts of GST-14-3-3γ protein, polarization values progressively increased to reach saturation, suggesting that a greater fraction of fluorescent peptide was bound to the 14-3-3 protein. The maximum assay window (∆mP = mP of bound peptide -mP of free peptide) reached approximately 150 mP with an estimated dissociation constant, Kd, of 0.412 ± 0.01 µM for the Raf peptide (Fig. 1B) . This FP signal is likely due to the specific interaction of TMR-pS259-Raf with 14-3-3γ because TMR-pS259-Raf with GST alone appears incapable of generating increases in FP signals ( Fig. 1A) and because the signal can be competed away by unlabeled peptides (Fig. 5) . These results provide a simple, quantitative "mix-and-measure" assay for studying 14-3-3 protein interactions.
The goal of the designed FP reaction is to provide a versatile assay that is simple for routine use and highly robust for HTS. We therefore optimized the performance of the assay and assessed its suitability for HTS applications. The dynamic assay range was determined based on concentration-dependent interactions of 14-3-3γ with fluorescently labeled Raf peptide (Fig. 1B) . The assay was sensitive to changes in 14-3-3 concentration up to about 0.5 µM. The quality of the assay was assessed by its S:N and Z′ factor (Fig.  1C) . The S:N value is significantly enhanced upon increasing the concentration of 14-3-3 proteins. It passes the minimal acceptance value of around 8, as set for the Analyst reader when 60 nM of 14-3-3 is used in the reaction and the ratio continues to improve to reach greater than 25. The Z′ factor incorporates the dynamic range and variability of an assay into a single metric. 32 Assays with Z′ factors larger than 0.5 and close to 1 are of high quality for HTS. The Z′ factor improves as the concentration of 14-3-3γ increases until reaching a plateau at around 0.5 µM (Fig. 1C) . Significantly, the Z′ factors are all greater than 0.7, and the S:N ratios are greater than 10 when 14-3-3γ concentration is greater than 0.1 µM, indicating a well-optimized assay. Accordingly, 0.5 µM of 14-3-3 proteins was used in the subsequent FP experiments.
To examine whether the GST tag has any effect on the 14-3-3 FP assay, a hexaHis-tagged 14-3-3γ protein was used in the same assay format. Both GST-and hexaHis-tagged 14-3-3γ give a similar interaction profile with an almost identical Kd value (0.42 ± 0.01 µM for His-14-3-3γ). There are 7 isoforms of 14-3-3 proteins known in mammalian cells. To illustrate a general use of the FP assay for 14-3-3 isoforms, we tested additional hexaHis-14-3-3 isoforms. Mixing TMR-pS259-Raf with increasing concentrations of hexaHis-14-3-3 isoforms led to progressively increased An HTS Assay for 14-3-3 Proteins polarization signals (Fig. 1D) . In this solution-based assay, isoforms of 14-3-3 proteins exhibited a slightly different binding affinity with the rhodamine-labeled Raf peptide. The estimated Kd values for tested isoforms were 0.42 ± 0.01 µM (γ), 0.86 ± 0.03 µM (η), 1.43 ± 0.04 µM (σ), 1.73 ± 0.07 µM (τ), 1.89 ± 0.04 µM (β), and 8.04 ± 0.55 µM (ε), respectively. The similarity in affinity for phosphopeptide among different isoforms of 14-3-3 reflects the highly conserved nature of the peptide binding site on 14-3-3, its amphipathic groove. 21 Whether the detected difference between epsilon and other isoforms is physiologically relevant remains to be tested. Clearly, this simple FP assay is applicable to 14-3-3 proteins in general, very likely including yeast and plant 14-3-3 proteins. 34, 35 To refine the 14-3-3 FP assay, we tested a range of different concentrations of the fluorescent Raf probe for 14-3-3 binding (0.5, 1, 2, and 5 nM) ( Fig. 2A) . A similar assay window of approximately 150 mP and a Kd of approximately 0.4 to 0.5 µM (0.53 ± 0.03, 0.44 ± 0.03, 0.46 ± 0.02, and 0.48 ± 0.02 µM when 0.5, 1, 2, and 5 nM of probe were used) were obtained for all concentrations. No change in assay windows was detected when as high as 50 nM of the probe peptide was used ( Fig. 2B) . Importantly, an S:N ratio of greater than 9 and a Z′ factor of greater than 0.5 were achieved under these conditions, demonstrating a robust assay even with a fluorophore concentration as low as 0.5 nM or as high as 50 nM (data not shown). This feature offers the flexibility of the assay for 14-3-3 binding. High probe concentration may be required under certain circumstances to overcome light scattering or fluorescence interference of the assay components such as the added compounds in HTS.
Examination of parameters that may influence the robustness of the assay
Good temporal stability would be a highly attractive feature for 14-3-3 affinity measurements and particularly for HTS. Thus, we examined the stability of the FP assay over time upon reagent mixing. TMR-pS259-Raf-peptide and GST-14-3-3γ were mixed and incubated at RT for a 42-h period. The polarization signals of each reaction in the 384-well microplates were recorded during this period (Fig. 3) . The results show that the assay is indeed very stable as revealed by virtually unchanged mP values and assay dynamic range (Fig. 3A,B) . Such assay stability will allow the dispensing of a large number of assay plates for scheduled reading of HTS results.
DMSO is a common solvent used in dissolving many natural and organic compounds as employed in small-molecule libraries. Therefore, the 14-3-3 FP assay must be able to tolerate the presence of DMSO if it is to be used for screening 14-3-3 modulators with a compound library. Increasing amounts of DMSO were added to the assay. It appears that up to 10% DMSO did not show any significant changes in mP signal, Kd, or dynamic range (Fig.  4A) . Further increase of the DMSO concentration slightly in- creased the mP value (Fig. 4B) . These results indicate that the FPbased 14-3-3 assay is stable in the presence of up to 10% DMSO.
Validation of the 14-3-3 FP assay with known peptide antagonists
To further validate the FP assay format for 14-3-3 studies and for HTS, we have developed a competition FP assay format by using several known peptide antagonists of 14-3-3. To achieve the desired sensitivity, the concentrations of fluorescent Raf peptide probe and 14-3-3 protein were carefully chosen to maximize the difference between the highest and lowest polarization values. A concentration of fluorescent Raf peptide probe of 1 nM was selected. This concentration of the peptide has high fluorescence intensity, which is expected to overcome any potential interference of weakly fluorescent compounds. A well-characterized 14-3-3 peptide antagonist, R18, was used as a competitor in the assay. 15, 16 R18 is a 20-amino acid, unphosphorylated peptide obtained from phage display libraries that exhibits a high affinity for 14-3-3 proteins in a solid-phase assay (Kd of 70-90 nM). 15 As shown in Figure 5 , R18 competitively decreased the FP signal when incubated with various concentrations of GST-14-3-3γ protein. IC 50 values of 1.4 ± 0.2, 2.4 ± 0.4, 3.5 ± 0.6, and greater than 10 µM were observed when 0.25, 0.5, 1.0, and 2.5 µM of GST-14-3-3γ were used, respectively (Fig. 5B) . Although the assay window increased with increasing concentrations of 14-3-3 protein (Fig. 1B) , the IC 50 values of the peptide competitors were also increased ( Fig. 5B) . Based on these results, we chose to use 0.5 µM of the 14-3-3γ protein for the competitive binding assay. This concentration, which is close to the Kd, strikes a balance between large dynamic range and sensitivity to inhibitors. To test the specificity of R18, a mutated form of R18, R18Lys, was used. In R18Lys, 2 negatively charged residues essential for 14-3-3 binding have been mutated to lysine. 16 An HTS Assay for 14- 3 R18Lys was incapable of competing with TMR-pS259-Raf (1 nM with 0.5 µM of 14-3-3γ), and the FP signal remained unchanged (Fig. 5A) . These results validate our 14-3-3 FP assay and establish conditions for competitive inhibitor studies, as required for HTS. Two additional 14-3-3 peptide antagonists were tested in this competition assay, both of which are derived from well-studied 14-3-3 client proteins, ASK1 and Raf-1. Biotin-pS259-Raf is a nonfluorescent version of the probe peptide. The pS967-ASK1 peptide is derived from the 14-3-3 binding site in ASK1. Both have been shown to inhibit 14-3-3/client-protein interactions. Indeed, both known 14-3-3 antagonists efficiently inhibited the interaction of TMR-pS259-Raf with GST-14-3-3γ. IC 50 was 1.3 ± 0.3 µM for biotin-pS259-Raf and 1.8 ± 0.2 µM for pS967-ASK1 (Fig. 5C) . Together, results from the competition FP assay with 3 known 14- . A mutant R18 that cannot bind 14-3-3 was used as a negative control. FP signals derived from the interaction of TMR-pS259-Raf with GST-14-3-3γ were recorded 1 h after incubation with increasing concentrations of R18 or its mutant derivative. Percentage FP signal in the R18 samples was expressed relative to the 14-3-3/Raf probe FP signal in the absence of R18 after correcting each sample for free probe peptide FP, as described in the Methods section. (B) Competition of R18 for the binding of TMR-pS259-Raf peptide to increasing concentrations of GST-14-3-3γ. (C) Assay validation with 14-3-3 recognition peptides from ASK1 and Raf-1. Nonfluorescent biotin-pS259-Raf and pS967-ASK1 were incubated with GST14-3-3γ and the peptide probe, TMR-pS259-Raf-1, as in panel A. The effect of an increasing amount of competitive peptides on 3-3 peptide antagonists validate the utility of the optimized 14-3-3 FP assay, which is particularly suited for HTS of 14-3-3 modulators. The tested 14-3-3 peptide inhibitors, such as R18, are valuable as positive controls in HTS applications.
High-throughput format development and miniaturization
The simple 1-step "mix-and-measure" format of the 14-3-3 FP assay and its demonstrated sensitivity allow this method to be used for automated operation in HTS in addition to its conventional use in 14-3-3 affinity determination. To test the utility of our optimized assay in an HTS format, we examined the precision and robustness of the assay in 384-well black microplates in a total volume of 50 µL using an automated robotic system. The well-to-well and plateto-plate variations were determined from experiments conducted on different days. In our test, each microplate contained an identical set of control reactions with 8 samples each of the following: 1) free TMR-pS259-Raf peptide (1 nM) alone gives minimal mP signal, 2) TMR-pS259-Raf with 14-3-3 (0.5 µM) defines the assay window, 3) TMR-pRaf with 14-3-3 in the presence of R18 (10 µM) demonstrates the minimal mP seen with maximal inhibition, and 4) TMR-pS259-Raf with 14-3-3 in the presence of R18Lys (10 µM) serves as a negative control. This test also provides an experimental basis for setting the operational threshold to identify potential positives in the primary screenings. Assay performance from forty 384-well microplates based on data from control samples 1) and 2) above is summarized online (see Supplemental Figures 1  and 2 ; http://jbx.sagepub.com/cgi/content/full/11/3/269/DC1). Both the free and bound peptide samples remained stable with minimal fluctuation. The average FP signal of free TMR-pS259-Raf peptide controls was 62 mP with a standard deviation of 1.8, and the average for bound peptide controls was 143 mP with a standard deviation of 2.5. The signal-to-noise ratios, as determined from each plate, were consistently higher than 10. The Z′ factor ranged from 0.7 to 0.9, demonstrating a robust and consistent assay with minimal variability. Thus, the FP assay for 14-3-3 binding based on the TMR-labeled pS259-Raf peptide is of excellent quality for HTS.
To test whether the 14-3-3 FP assay could be miniaturized for potential use of the 1536-well plate format, we examined its performance with reduced volumes. The same concentrations of each assay component were maintained in a volume of 20 µL. As described above, each component was mixed and the reactions were recorded with the Analyst plate reader in a 384-well plate. An assay window of 62.3 mP with 3.9 SD was achieved as sampled from 40 assay plates. The S:N values were 8 and greater, with an average S:N of 11.8. The obtained Z′ factors were mostly greater than 0.5, suggesting a robust assay suitable for HTS. Further evaluation of the assay performance in the volumes of 10 to 50 µL gave rise to Z′ factors ranging from 0.6 to 0.8 (data not shown). These results suggest the feasibility of using the 14-3-3 FP assay in an ultra-HTS format.
SUMMARY
A 1-step "mix-and-measure" fluorescence polarization method has been developed and validated for studying 14-3-3 proteins. The interaction of 14-3-3 with a fluorescently tagged recognition motif from Raf-1, TMR-pS259-Raf, was used as a model system. Binding of 14-3-3 proteins to the Raf peptide probe gave rise to large polarization signals with robust performance. GST-tagged and hexaHis-tagged 14-3-3 proteins exhibited similar affinity in the assay, allowing these 14-3-3 fusion proteins to be used without the need for proteolytic cleavage. This is a general 14-3-3 assay that has the propensity to work on all 14-3-3 isoforms with almost any 14-3-3 binding peptide from its client proteins. Experiments with multiple peptide antagonists show specificity of the probe/14-3-3 interaction and also show that the assay can be used to search for compounds that disrupt 14-3-3/ligand binding. Because of its excellent stability, DMSO tolerance, and simplicity, this assay is particularly suited for HTS. In this format, it has an excellent S:N ratio, Z′ factor, and minimal plate-to-plate variation. Furthermore, the assay was miniaturized to a volume of 20 µL with excellent performance, suggesting a possibility of adapting it to a 1536-well plate format for ultra-HTS of small-molecule 14-3-3 inhibitors. The availability of this well-designed, 1-step FP assay is expected to facilitate the screening of large chemical compound libraries for 14-3-3 inhibitors.
